Attovia Therapeutics

News

Quartet of biotechs join Nasdaq after stellar IPOs

Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.

News

Apnimed IPO raises $192m, as three other biotechs set terms

Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.

News

Two more biotechs, Attovia and Braveheart, join the IPO line

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.

News

Merida raises $121m for Graves drug, and other financings

Our round-up of recent biotech financings includes rounds for Merida, Glycomine, Attovia, Imbria, and Solu Therapeutics.

News

TIGIT developer iTeos raises $120m, and other financings

Our round-up of notable biotech financings in the last week includes a $120 million direct offering for immunology and inflammation biotech iTeos, and private rounds for L

Quartet of biotechs join Nasdaq after stellar IPOs

Apnimed IPO raises $192m, as three other biotechs set terms

Two more biotechs, Attovia and Braveheart, join the IPO line

Merida raises $121m for Graves drug, and other financings

TIGIT developer iTeos raises $120m, and other financings

Claude Science outperforms experts in protein binder task

Discover a new era of healthcare panel engagement: Grounded ...

Attovia Therapeutics

Editor's Picks